ニボルマブの世界市場：2025年

ニボルマブの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR13.4%で32億米ドルに成長すると予測されています。予測期間の成長は、個別化医療、新たな適応症、世界のがん治療へのアクセス、併用療法の進歩に起因すると考えられます。予測期間における主な動向には、バイオマーカー主導型治療、新抗原ワクチン、免疫療法レジメンの強化、長期追跡調査などがあります。

がんの有病率の増加は、ニボルマブ市場の今後の成長を牽引すると予想されます。がんは、異常な細胞が制御不能に増殖し、正常な境界を突き破って他の臓器に転移したり、周囲の組織に浸潤したりすることで、体内のほぼすべての臓器や組織に発生する可能性のある疾患群です。ニボルマブは、がん細胞が免疫系を抑制するのを防ぎ、免疫系ががん細胞を攻撃・破壊できるようにすることで、さまざまな種類のがんの治療に使用されます。例えば、2024年7月、オーストラリア政府機関であるオーストラリア保健福祉研究所（Australian Institute of Health and Welfare）は、オーストラリアで診断されたがんの症例数が2021年の15万6,781例から2022年には16万570例に増加し、1年間で3,789例増加したと報告しました。その結果、がんの有病率の上昇がニボルマブ市場の成長を後押ししています。

非小細胞肺がん（NSCLC）の罹患率の上昇は、当面のニボルマブ市場成長の顕著な促進要因になる見通しです。NSCLCは、肺の上皮細胞から発生する肺がんの一種で、ニボルマブの主な対象領域です。ニボルマブは、進行した非小細胞肺がん（NSCLC）の治療薬として承認されており、その有効性が証明されています。米国臨床腫瘍学会のデータによると、2023年3月に米国で肺がんと診断される患者は23万8,340人（男性11万7,550人、女性12万790人）と推定されています。これらの症例のうち、NSCLCが優勢なサブタイプであり、肺がん診断全体の約81％を占めています。その結果、非小細胞肺がん（NSCLC）の罹患率の上昇は、ニボルマブ市場の手ごわい成長促進要因となっています。

当レポートは、世界のニボルマブ市場について調査し、市場の概要とともに、タイプ別、投与経路別、用途別、エンドユーザー別、タイプ別、地域・国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 ニボルマブ市場の特徴

第3章 ニボルマブ市場の動向と戦略

第4章 ニボルマブ市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 ニボルマブの世界成長分析と戦略分析フレームワーク

• 世界ニボルマブPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のニボルマブ市場の成長率分析
• 世界のニボルマブ市場規模実績と成長、2019年～2024年
• 世界のニボルマブ市場規模と成長予測、2024年～2029年、2034年予想
• 世界のニボルマブ総獲得可能市場（TAM）

第6章 ニボルマブ市場セグメンテーション

• 世界のニボルマブ市場、タイプ別セグメンテーション、実績および予測、2019年～2024年、2024年～2029年予測、2034年予測
• 注射液4mL
• 注射液10mL
• 世界のニボルマブ市場、投与経路別セグメンテーション、実績および予測、2019年～2024年、2024年～2029年、2034年
• 静脈内
• その他
• 世界のニボルマブ市場、用途別セグメンテーション、実績および予測、2019年～2024年、2024年～2029年予測、2034年予測
• 悪性黒色腫
• 非小細胞肺がん（NSCLC）
• 悪性胸膜中皮腫
• 古典的ホジキンリンパ腫（CHL）
• 頭頸部扁平上皮がん（SCCHN）
• 腎細胞がん（RCC）
• その他
• 世界のニボルマブ市場、エンドユーザー別セグメンテーション、実績および予測、2019～2024年、2024～2029年、2034年
• クリニック
• 病院
• その他
• 世界のニボルマブ市場、注射剤4mLのサブセグメンテーション、タイプ別、実績および予測、2019年～2024年、2024年～2029年予測、2034年予測
• 単回投与バイアル
• マルチドーズバイアル
• 世界のニボルマブ市場、注射剤10mLのサブセグメンテーション、タイプ別、実績および予測、2019年～2024年、2024年～2029年予測、2034年予測
• 単回投与バイアル
• マルチドーズバイアル

第7章 ニボルマブ市場の地域別および国別分析

• 世界のニボルマブ市場、地域別、実績および予測、2019年～2024年、2024年～2029年予測、2034年予測
• 世界のニボルマブ市場、国別、実績および予測、2019年～2024年、2024年～2029年予測、2034年予測

第8章 アジア太平洋のニボルマブ市場

第9章 中国のニボルマブ市場

第10章 インドのニボルマブ市場

第11章 日本のニボルマブ市場

第12章 オーストラリアのニボルマブ市場

第13章 インドネシアのニボルマブ市場

第14章 韓国のニボルマブ市場

第15章 西欧のニボルマブ市場

第16章 英国のニボルマブ市場

第17章 ドイツのニボルマブ市場

第18章 フランスのニボルマブ市場

第19章 イタリアのニボルマブ市場

第20章 スペインのニボルマブ市場

第21章 東欧のニボルマブ市場

第22章 ロシアのニボルマブ市場

第23章 北米のニボルマブ市場

第24章 米国のニボルマブ市場

第25章 カナダのニボルマブ市場

第26章 南米のニボルマブ市場

第27章 ブラジルのニボルマブ市場

第28章 中東のニボルマブ市場

第29章 アフリカのニボルマブ市場

第30章 ニボルマブ市場の競合情勢と企業プロファイル

• ニボルマブ市場の競合情勢
• ニボルマブ市場企業プロファイル
  • Pfizer Inc.
  • Johnson &Johnson Services Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck &Co. Inc.
  • AbbVie Inc.

第31章 ニボルマブ市場その他の大手および革新的企業

• Novartis AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Chugai Pharmaceutical Co. Ltd.
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Ono Pharmaceutical Co. Ltd.
• Kyowa Kirin Co. Ltd.

第32章 世界のニボルマブ市場の競合ベンチマーキングとダッシュボード

第33章 ニボルマブ市場における主要な合併と買収

第34章 ニボルマブ市場の最近の動向

第35章 ニボルマブ市場の潜在的可能性の高い国、セグメント、戦略

• 2029年のニボルマブ市場- 最も新しい機会を提供する国
• 2029年のニボルマブ市場- 最も新しい機会を提供するセグメント
• 2029年のニボルマブ市場- 成長戦略
  • 市場動向に基づく戦略
  • 競合戦略

第36章 付録

Nivolumab is an immunoglobulin G4 (IgG4) fully human antibody that targets programmed cell death protein 1 (PD1). It is approved at a dosage of 3 mg/kg for the treatment of metastatic or unresectable melanoma, metastatic non-small cell lung cancer following platinum-based chemotherapy, and metastatic renal cell carcinoma in the second-line setting. Nivolumab is a targeted therapy medication employed in the management and treatment of various types of cancer, and it operates by enhancing the immune system's response to cancer cells.

Nivolumab is available in two main formulations such as an injection of 4 mL and an injection of 10 mL. The 40 mg/4 mL (10 mg/mL) solution of nivolumab is provided in single-use vials. This formulation is utilized in the treatment of melanoma, non-small cell lung cancer (NSCLC), and Hodgkin lymphoma. It is administered via intravenous and other routes for the treatment of conditions such as melanoma, NSCLC, malignant pleural mesothelioma, classical Hodgkin lymphoma (CHL), squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), and other cancer types. Nivolumab is used in clinical settings, hospitals, and other healthcare facilities for cancer treatment.

The nivolumab market research report is one of a series of new reports from The Business Research Company that provides nivolumab market statistics, including nivolumab industry global market size, regional shares, competitors with a nivolumab market share, detailed nivolumab market segments, market trends and opportunities and any further data you may need to thrive in the nivolumab industry. This nivolumab market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nivolumab market size has grown rapidly in recent years. It will grow from $1.69 billion in 2024 to $1.94 billion in 2025 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to immunotherapy advancements, increased incidence of cancer, clinical trial success, regulatory approvals.

The nivolumab market size is expected to see rapid growth in the next few years. It will grow to $3.2 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to personalized medicine, emerging indications, global access to cancer care, advancements in combination therapies. Major trends in the forecast period include biomarker-driven treatment, neoantigen vaccines, enhanced immunotherapy regimens, long-term follow-up studies.

The increasing prevalence of cancer is expected to drive the growth of the nivolumab market in the future. Cancer is a group of diseases that can occur in nearly any organ or tissue in the body when abnormal cells grow uncontrollably, break through normal boundaries, and either spread to other organs or invade surrounding tissues. Nivolumab is used to treat various types of cancer by preventing cancer cells from suppressing the immune system, allowing the immune system to attack and destroy the cancer cells. For example, in July 2024, the Australian Institute of Health and Welfare, an Australian government agency focused on providing health and welfare data and analysis, reported that the number of cancer cases diagnosed in Australia increased from 156,781 in 2021 to 160,570 in 2022, marking an increase of 3,789 cases over the one-year period. As a result, the rising prevalence of cancer is fueling the growth of the nivolumab market.

The increasing incidence of non-small cell lung cancer (NSCLC) is poised to be a prominent driver for the Nivolumab market's growth in the foreseeable future. NSCLC, a prevalent form of lung cancer originating in the epithelial cells of the lungs, is a major area of focus for Nivolumab. The drug has garnered approval for the treatment of advanced non-small cell lung cancer (NSCLC) owing to its proven efficacy in addressing this specific condition. Notably, data from the American Society of Clinical Oncology reveals that an estimated 238,340 individuals (comprising 117,550 men and 120,790 women) are anticipated to receive a lung cancer diagnosis in the United States in March 2023. Among these cases, NSCLC is the predominant subtype, representing approximately 81% of all lung cancer diagnoses. Consequently, the increased incidence of non-small cell lung cancer (NSCLC) stands as a formidable growth driver for the Nivolumab market.

Prominent companies operating within the Nivolumab market are placing a significant emphasis on the development of innovative drugs aimed at enhancing patient care and sustaining their market positions. The creation of novel drugs holds the potential to improve treatment outcomes for patients grappling with various medical conditions. As an illustration, in May 2022, Bristol-Myers Squibb Co., a US-based pharmaceutical company primarily dedicated to therapeutic endeavors encompassing cancer, cardiovascular health, immunology, and fibrotic conditions, disclosed the FDA's approval of two Nivolumab-based regimens. These regimens included Nivolumab in combination with fluoropyrimidine and platinum-containing chemotherapy and Nivolumab paired with Yervoy (ipilimumab), for the first-line treatment of adult patients dealing with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 status.

In November 2022, Lyvgen Biopharma Co. Ltd., a China-based biotechnology firm specializing in cancer treatment, entered into a collaborative partnership with Bristol-Myers Squibb Co. The collaboration's focal point is the assessment of LVGN7409 in conjunction with Nivolumab, targeting patients with non-small cell lung cancer. This combination therapy concurrently addresses the co-stimulatory checkpoint CD40 and the co-inhibitory checkpoint PD-1. This multifaceted approach is envisioned to enhance the effectiveness of immunotherapy for patients confronting diseases that exhibit resistance or refractoriness. Bristol-Myers Squibb Co. is a US-based pharmaceutical company with a primary focus on therapeutic domains spanning cancer, cardiovascular health, immunology, and fibrotic disorders, inclusive of pioneering developments in Nivolumab.

Major companies operating in the nivolumab market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Nippon Kayaku Co. Ltd., Luye Pharma AG, Genentech Inc., Taiho Pharmaceutical Co. Ltd., SymBio Pharmaceuticals Ltd., Xbrane Biopharma AB, NeuClone Therapeutics Inc.

North America was the largest region in the nivolumab market in 2024. The regions covered in nivolumab report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nivolumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nivolumab market consists of sales of opdivo, nivolumab injection, generic Nivolumab. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nivolumab Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nivolumab market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nivolumab ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nivolumab market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Injection 4mL; Injection 10mL
• 2) By Route Of Administration: Intravenous; Other Routes Of Administration
• 3) By Application: Melanoma; Non-small Cell Lung Cancer (NSCLC); Malignant Pleural Mesothelioma; Classical Hodgkin Lymphoma (CHL); Squamous Cell Carcinoma Of The Head And Neck (SCCHN); Renal Cell Carcinoma (RCC); Other Applications
• 4) By End-User: Clinic; Hospital; Other End-Users
• Subsegments:
• 1) By Injection 4mL: Single-Dose Vial; Multi-Dose Vial
• 2) By Injection 10mL: Single-Dose Vial; Multi-Dose Vial
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nivolumab Market Characteristics

3. Nivolumab Market Trends And Strategies

4. Nivolumab Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Nivolumab Growth Analysis And Strategic Analysis Framework

• 5.1. Global Nivolumab PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Nivolumab Market Growth Rate Analysis
• 5.4. Global Nivolumab Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Nivolumab Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Nivolumab Total Addressable Market (TAM)

6. Nivolumab Market Segmentation

• 6.1. Global Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injection 4mL
• Injection 10mL
• 6.2. Global Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous
• Other Routes Of Administration
• 6.3. Global Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Melanoma
• Non-small Cell Lung Cancer (NSCLC)
• Malignant Pleural Mesothelioma
• Classical Hodgkin Lymphoma (CHL)
• Squamous Cell Carcinoma Of The Head And Neck (SCCHN)
• Renal Cell Carcinoma (RCC)
• Other Applications
• 6.4. Global Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinic
• Hospital
• Other End-Users
• 6.5. Global Nivolumab Market, Sub-Segmentation Of Injection 4mL, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Dose Vial
• Multi-Dose Vial
• 6.6. Global Nivolumab Market, Sub-Segmentation Of Injection 10mL, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Dose Vial
• Multi-Dose Vial

7. Nivolumab Market Regional And Country Analysis

• 7.1. Global Nivolumab Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Nivolumab Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nivolumab Market

• 8.1. Asia-Pacific Nivolumab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nivolumab Market

• 9.1. China Nivolumab Market Overview
• 9.2. China Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nivolumab Market

• 10.1. India Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nivolumab Market

• 11.1. Japan Nivolumab Market Overview
• 11.2. Japan Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nivolumab Market

• 12.1. Australia Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nivolumab Market

• 13.1. Indonesia Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nivolumab Market

• 14.1. South Korea Nivolumab Market Overview
• 14.2. South Korea Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nivolumab Market

• 15.1. Western Europe Nivolumab Market Overview
• 15.2. Western Europe Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nivolumab Market

• 16.1. UK Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nivolumab Market

• 17.1. Germany Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nivolumab Market

• 18.1. France Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nivolumab Market

• 19.1. Italy Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nivolumab Market

• 20.1. Spain Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nivolumab Market

• 21.1. Eastern Europe Nivolumab Market Overview
• 21.2. Eastern Europe Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nivolumab Market

• 22.1. Russia Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nivolumab Market

• 23.1. North America Nivolumab Market Overview
• 23.2. North America Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nivolumab Market

• 24.1. USA Nivolumab Market Overview
• 24.2. USA Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nivolumab Market

• 25.1. Canada Nivolumab Market Overview
• 25.2. Canada Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nivolumab Market

• 26.1. South America Nivolumab Market Overview
• 26.2. South America Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nivolumab Market

• 27.1. Brazil Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nivolumab Market

• 28.1. Middle East Nivolumab Market Overview
• 28.2. Middle East Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nivolumab Market

• 29.1. Africa Nivolumab Market Overview
• 29.2. Africa Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nivolumab Market Competitive Landscape And Company Profiles

• 30.1. Nivolumab Market Competitive Landscape
• 30.2. Nivolumab Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Nivolumab Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca plc
• 31.5. GlaxoSmithKline plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Amgen Inc.
• 31.9. Regeneron Pharmaceuticals Inc.
• 31.10. Astellas Pharma Inc.
• 31.11. Chugai Pharmaceutical Co. Ltd.
• 31.12. Daiichi Sankyo Company Limited
• 31.13. Eisai Co. Ltd.
• 31.14. Ono Pharmaceutical Co. Ltd.
• 31.15. Kyowa Kirin Co. Ltd.

32. Global Nivolumab Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nivolumab Market

34. Recent Developments In The Nivolumab Market

35. Nivolumab Market High Potential Countries, Segments and Strategies

• 35.1 Nivolumab Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Nivolumab Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Nivolumab Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer